Fountainhead AM
NBIX icon

Fountainhead AM’s Neurocrine Biosciences NBIX Stock Holding History

Fountainhead AM’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-84
Closed -$14.2K – 171
2026
Q2 		$14.2K Buy
+84
New +$12.5K 0.01% 181
2021
Q1 		– Sell
-2,124
Closed -$204K – 61
2020
Q4 		$204K Buy
+2,124
New +$205K 0.13% 51

Other funds holding NBIX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $102B AUM 35.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Fountainhead AM's NBIX Position: Q3 2026 in Review

Fountainhead AM sold out of Neurocrine Biosciences (NBIX) in Q3 2026, closing a stake of 84 shares — an estimated $14.2K sold.

Fountainhead AM first reported a position in NBIX in Q4 2020 and held it in 2 quarters. The position peaked at $204K in Q4 2020. 630 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Fountainhead AM reported no remaining Neurocrine Biosciences position as of Q3 2026 after selling out during the quarter.
  • Fountainhead AM sold 84 Neurocrine Biosciences shares in Q3 2026, an estimated $14.2K.
  • Fountainhead AM first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 2 quarters.
  • Fountainhead AM's Neurocrine Biosciences position peaked at $204K in Q4 2020.
  • 630 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Fountainhead AM's 13F filing for Q3 2026, filed 5 Nov 2026.